GlassScriptPhysician profile
Ricardo Gomez
NPI 1699797191
$6,185.20
in general payments reported to CMS, 2019-2025
37 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $272 · 2021: $418 · 2022: $616 · 2023: $1,024 · 2024: $1,794 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,568 · Travel and Lodging: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,568.34 |
| Travel and Lodging | $717.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $928.37 | 2022-2025 | Minimed 780g |
| Beta Bionics, INC. | $676.79 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Novo Nordisk INC | $579.58 | 2019-2025 | Sogroya, Norditropin |
| Dexcom, INC. | $528.06 | 2022-2025 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $453.60 | 2022-2025 | Skytrofa |
| Abbvie INC. | $327.16 | 2019-2025 | |
| Ultragenyx Pharmaceutical INC. | $289.90 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $269.63 | 2019-2024 | Strensiq |
| Tolmar, INC. | $249.53 | 2023-2025 | Fensolvi |
| Mannkind Corporation | $196.82 | 2025 | |
| Sanofi-Aventis U.S. LLC | $188.73 | 2023-2025 | |
| Pfizer INC. | $156.02 | 2021-2025 | |
| Kyowa Kirin, INC. | $153.10 | 2023-2025 | Crysvita |
| Arbor Pharmaceuticals, INC. | $143.95 | 2019-2022 | |
| Lilly USA, LLC | $143.16 | 2019-2023 | Baqsimi |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $95.29 | 2023-2024 | Triptodur, Triptodur |
| Tandem Diabetes Care, INC. | $79.07 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Rhythm Pharmaceuticals, INC. | $78.75 | 2022-2024 | Imcivree, Imcivree |
| Medtronic Minimed, INC. | $78.64 | 2019 | |
| Abbott Laboratories | $63.97 | 2023-2025 | Freestyle Libre 3 |
| Lifescan, INC. | $63.18 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $59.87 | 2021-2024 | Gvoke Hypopen |
| Endo Pharmaceuticals INC. | $50.54 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $48.75 | 2024-2025 | |
| Chiesi USA, INC. | $43.78 | 2024-2025 | Myalept |
| Insulet Corporation | $32.67 | 2019-2020 | |
| Zealand Pharma US, INC. | $27.31 | 2021 | |
| Biomarin Pharmaceutical INC. | $25.64 | 2024 | Voxzogo 1.2mg |
| Endo USA, INC. | $23.67 | 2025 | Supprelin |
| Tolmar Pharmaceuticals, INC. | $22.33 | 2022 | |
| Alcresta Therapeutics, INC. | $18.53 | 2024 | Relizorb |
| Stryker Corporation | $17.99 | 2023 | Actishield Cf |
| Soleno Therapeutics, INC. | $16.79 | 2025 | Vykat Xr |
| Companion Medical, INC. | $15.80 | 2020 | |
| Alnylam Pharmaceuticals INC. | $13.90 | 2024 | Oxlumo |
| Eton Pharmaceuticals, INC. | $12.19 | 2023 | Alkindi |
| Ferring Pharmaceuticals INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.